The treatment landscape for patients with multiple myeloma (MM) has evolved rapidly in recent years due to an enhanced understanding of the heterogeneous nature of the disease. As novel therapies start to be incorporated in the frontline and relapsed settings, clinicians are frequently unsure of how to appropriately choose therapies to improve patient outcomes.
The learning objectives of this program are:
The target audience for this activity is hematologists and oncologists who treat patients with MM. Physicians, nurses, and other health care professionals interested in the treatment of MM are also invited to participate.
December 10, 2021
Registration and Lunch: 2:15 PM – 3:00 PM EST
Scientific Session: 3:00 PM- 5:00 PM EST